Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Canadians Watch U.S. Reform Effort Closely
American health care reform has become a "hot topic north of the border," the Washington Times reports. "If Mr. Obama succeeds, the U.S. could draw even more Canadian doctors and nurses to the U.S., exacerbating a shortage of medical professionals, said Dr. Brian Day, a Canadian health care critic and former head of the Canadian Medical Association. If Mr. Obama fails, perhaps Canada could open its system to "medical tourism" from the U.S., Dr. Day said." Under the Canadian system, everyone is insured and has "access to basic health care without ever seeing a doctor or hospital bill." But 70% of Canadians also have "some form of supplemental health insurance," in part because of long wait times for tests and treatments under the government plan. For Canadian citizens who become ill in the U.S., it is often cheaper to "ride on a private Lear jet back to Canada" than to be treated in a U.S. hospital.
generic viagra online
Nucletron Releases Comprehensive Film-and Volume-Based Planning System For Wide Variety Of Brachy Solutions
Nucletron, a knowledge-based leader in radiation oncology,
News of the day
Calorie-Burning 'Brown Fat' Found In Adults, Especially Women
Keeping your baby fat turns out to be a good thing, as long as it is "brown fat"- the kind that burns calories, according to a study that found adults have much more of this type of fat than previously thought. The results, which suggest a new way to treat obesity, were presented at The Endocrine Society"s 91st Annual Meeting in Washington, D.C.
Health Insurance

Drug Manufacturer Receives Fast Track Designation From FDA

Pharmaceutical firm Biogen Idec announced that the American drug watchdog the Food and Drug Administration (FDA) has granted Fast Track designation for its multiple sclerosis (MS) drug PEGylated interferon beta-1a (BIIB017). The company is currently enrolling patients in a global Phase III study evaluating the effectiveness and safety of either bi-weekly or once-monthly injections of the therapy in people with relapsing remitting MS. If the trial reports promising results it means that people could inject their medication less often without sacrificing effectiveness. The FDA"s Fast Track program is designed to speed up the review of new drugs that are intended to treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs. Biogen Idec plans to enrol more than 1,200 patients with relapsing remitting MS in the Phase III, randomized, double-blind, placebo-controlled trial called ADVANCE designed to evaluate the effectiveness and safety of PEGylated interferon beta-1a. Patients interested in finding out more about the ADVANCE trial should speak to their neurologist or email ADVANCEstudy@biogenidec.com Multiple Sclerosis Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009